Characterization of a B-cell immunodominant epitope of human T-lymphotropic virus type 1 (HTLV-I) envelope gp46

Michael Dale Lairmore, Donna L. Rudolph, Beverly D. Roberts, Charlene S. Dezzutti, Renu B. Lal

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


The immune response elicited by a synthetic peptide derived from an immunodominant external envelope region (Env-5, amino acids 242-257) of human T-lymphotropic virus type 1 (HTLV-I) was tested in a rabbit model of HTLV-I infection. The synthetic peptide elicited a strong antibody response to the HTLV-I envelope protein gp46; however, these antibodies failed to inhibit HTLV-I-mediated cell fusion. Immunized rabbits were not protected from HTLV-I infection as determined by seroconversion to viral core proteins by immunoblot, HTLV-I p24 antigen detection in lymphocyte cultures and polymerase chain reaction for the HTLV-I provirus in lymphocyte DNA. Env-5 peptide immunization failed to induce T-cell lymphocyte proliferative responses in rabbits, but induced antibody responses in T-cell deficient Balb c nu/nu mice suggesting that the antigenic determinant represented by the Env-5 peptide is primarily a B-cell epitope. These results further define an immunodominant epitope of the HTLV-I envelope protein and suggest that potential synthetic peptide vaccines against HTLV-I infection must contain multiple antigens that induce both humoral and cellular immune reactivity.

Original languageEnglish (US)
Pages (from-to)11-20
Number of pages10
JournalCancer Letters
Issue number1
StatePublished - Sep 14 1992
Externally publishedYes


  • animal model
  • human
  • human T-lymphotropic virus type 1
  • synthetic peptide
  • vaccine

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology


Dive into the research topics of 'Characterization of a B-cell immunodominant epitope of human T-lymphotropic virus type 1 (HTLV-I) envelope gp46'. Together they form a unique fingerprint.

Cite this